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Introduction
Recessive mutations in phosphatase and tensin homologue–
induced kinase (PINK1) cause early-onset Parkinson’s dis-
ease (PD), an incurable neurodegenerative movement disorder 
(Valente et al., 2004). When mitochondria are stressed, PINK1 
recruits Parkin to promote the autophagic clearance of mito-
chondria, and genetically PINK1 operates in this context up-
stream of Parkin (Clark et al., 2006; Park et al., 2006; Narendra 
et al., 2010). Also under nonstressed, endogenous conditions, 
the loss of PINK1 results in mitochondrial defects. These de-
fects include reduced ATP levels, cristae defects, and a less neg-
ative mitochondrial membrane potential. Important aspects of 
these phenotypes can be explained by the inability of PINK1 
mutants to maintain phosphorylation of serine 250 in subunit 
NdufA10 of complex I in the electron transport chain (ETC). 
This defect results in inefficient electron transfer between com-
plex I and ubiquinone in PINK1 mutant fruit fly–, mouse-, 
and patient-derived cells (Clark et al., 2006; Park et al., 2006; 
Yang et al., 2006; Gautier et al., 2008; Morais et al., 2009, 
2014; Vos et al., 2012). Hence, activation of pathways that 
increase ETC activity may bypass this electron transfer defect 
in PINK1 mutants (Vos et al., 2012, 2013) and may constitute a 
promising therapy for PD.
Changes in lipid content are associated with aging and 
with neurodegeneration, including Alzheimer’s disease and 
neurodegeneration with brain iron accumulation (Filippov et 
al., 2012; Aoun and Tiranti, 2015; Jazvinšćak Jembrek et al., 
2015). Likewise, alterations in lipid metabolism have been de-
scribed in models of PD as well (Lim et al., 2012; Tyurina et 
al., 2015). However, whether the mitochondrial dysfunction in 
PINK1 mutants is under the control of specific changes in lipid 
content has not been investigated, nor has it been thoroughly 
explored whether mitochondrial dysfunction can be modified 
by alterations in lipid content.
In this study, we present an unbiased genetic screen and 
identify fatty acid synthase (FASN) as a dominant suppressor of 
PINK1 deficiency. Given the strong interest in FASN inhibition 
in the field of oncology, pharmacological inhibitors exist, and 
we show that they can also rescue PINK1 deficiency in fly-, 
mouse-, and patient-derived neurons, connecting the function of 
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FASN to the mitochondrial defects in PINK1 mutants. Interest-
ingly, among several changes in phospholipid levels in PINK1 
mutants, we show that the production of the mitochondrial-spe-
cific lipid, cardiolipin (CL), is inhibited. Our data indicate that 
CL, but not other phospholipids, plays a role in the regulation of 
electron transfer between complex I and ubiquinone. Our work 
suggests that CL regulates electron transfer in complex I and 
also indicates that strategies to increase CL levels are protective 
against mitochondrial dysfunction in PINK1 mutants.
Results
Identification of FASN as dominant 
suppressor of PINK1 deficiency
In a genetic screen in fruit flies (Vos et al., 2012), we identified 
10 ethyl methanesulfonate–induced mutations that dominantly 
suppress pink1 mutant phenotypes. When heterozygous, these 
suppressors rescue decreased ATP levels, mitochondrial mor-
phological defects, and the flying deficit of the pink1B9-null 
mutant flies (Fig. 1 A). We used classical deficiency mapping 
and whole genome sequencing and found a nonsynonymous 
lesion in 7 of the 10 suppressor mutants (Fig. S1, A and B). 
One of them, opa1, had been previously identified as a pink1 
suppressor (Poole et al., 2008). The strongest pink1 suppres-
sor is a loss-of-function lesion in FASN2 (FASN2/CG3524/v(2)
k05816; Fig. 1 A) and is specific to pink1 because heterozygous 
FASN2 loss only weakly suppresses parkin-null mutant pheno-
types (Fig. S1 C). In addition, all the other FASN2 alleles that 
we obtained also suppress the flight defects and the mitochon-
drial morphological defects in pink1B9 mutant flies (Fig. 1, B–F; 
and Fig. S1, E and F). Note that heterozygous FASN2 animals 
in an otherwise wild-type background (pink1RV) did not show 
defects (Fig. 1, B–F; and Fig. S1, E and F). In addition, expres-
sion of wild-type FASN2 rescued the lethality of the different 
homozygous FASN2 alleles we isolated, further indicating they 
are loss-of-function mutations (Fig. S1 D). Hence, partial loss 
of FASN2 rescues pink1 mutant defects.
Pharmacological inhibition of FASN  
rescues PINK1-deficient flight defects  
and ATP levels
FASN is an evolutionarily conserved enzyme that catalyzes the 
synthesis of the free fatty acid palmitate (Fig. 2 A; Chirala and 
Wakil, 2004). Given the immense interest to inhibit FASN in 
oncology and metabolic disease (Menendez and Lupu, 2007; 
Ogino et al., 2008; Nguyen et al., 2010; Park et al., 2015), sev-
eral inhibitors of this enzyme have been developed (Menendez 
and Lupu, 2007). Because inhibitors often have several off-tar-
get effects, we have tested three independent drugs, Cerulenin, 
Irgasan, and Orlistat, that block the second, sixth, and seventh 
steps of the FASN reaction, respectively (Fig.  2  A; Omura, 
1976; Kapoor et al., 2004). When 1-d-old adult pink1 mutant 
Drosophila melanogaster that display flight and mitochondrial 
defects were placed on medium with one of these compounds, 
the flies showed a progressive and dose-dependent improvement 
in flying, and their decreased ATP levels were significantly re-
stored. No significant effect was observed in wild-type control 
flies that were fed with Cerulenin, Irgasan, or Orlistat (Fig. 2, C, 
E, and G). Hence, pharmacological inhibition of FASN rescues 
phenotypes in Pink1-deficient flies, and, in the remainder of our 
study, we used genetics and Cerulenin.
In addition to a rescue in flight and ATP levels, the charac-
teristic mitochondrial clustering and blebbing defects of pink1 
mutant mitochondria in muscles of larvae were rescued after 
Cerulenin incubation (Fig. 3, A and B). Furthermore, Cerule-
nin also acutely restores a normal dense mitochondrial cristae 
structure in pink1 mutant thorax muscles. We placed 1-d-old 
adult Pink1 mutant animals that show mitochondrial cristae 
morphology defects on Cerulenin for 3 d and observed that the 
muscle tissue and mitochondrial morphology and cristae struc-
ture of Pink1 mutants that were fed Cerulenin appeared much 
more like those in control thoraces (with or without Cerulenin), 
and they show much fewer signs of degeneration (Figs. 3 C and 
S2, A–C). Interestingly, the rescue we observe is specific for 
Pink1-induced phenotypes and not for Parkin because 1-d-old 
Parkin mutant flies that are on Cerulenin for 3 d are not rescued 
(Fig. S2 D). Although Pink1 and Parkin act together for some 
aspects of their function (Clark et al., 2006; Park et al., 2006; 
Narendra et al., 2009; Haddad et al., 2013), the effects of FASN 
inhibition appear to be specific for pathways under the control 
of Pink1 (Vilain et al., 2012; Pogson et al., 2014).
PINK1 rescue by FASN inhibition is 
evolutionarily conserved
To assess whether the rescue of Pink1-associated phenotypes 
by inhibition of FASN is evolutionarily conserved, we turned to 
Pink1−/−-deficient mouse- and patient-derived cells. Incubation 
of Pink1−/− mouse embryonic fibroblasts (MEFs) or patient- 
derived fibroblasts with Cerulenin rescues the decreased ATP 
levels (Fig. 3, D and E). Compared with age-matched controls, 
dopaminergic neurons derived from induced pluripotent stem 
cells (iPSCs) from different PINK1 carriers also displayed sig-
nificantly lower ATP levels, although this effect was less pro-
nounced than in the fibroblasts. Nonetheless, these lower ATP 
levels in PINK1 mutant human dopaminergic neurons were also 
rescued when incubated with Cerulenin (Fig. 3 F). Hence, inhi-
bition of FASN rescues PINK1 deficiency in flies and in mouse- 
and patient-derived cells.
Loss of FASN decreases palmitate levels in 
Pink1 deficiency
We used an enzyme-linked assay and measurement of optical 
density to assess free fatty acid levels that also include free pal-
mitate. Genetic or pharmacological inhibition of FASN in flies 
and in MEFs showed a trend toward lower free fatty acid levels 
compared with controls, but the differences were statistically 
not significant (Fig. 4, A–C, two left bars). We then resorted to 
gas chromatography–coupled mass spectrometry to directly as-
sess free palmitate levels and found that these were significantly 
lower in animals treated with Cerulenin (Fig.  4  D, two left 
bars), in line with the expected result when inhibiting FASN. 
Surprisingly, pink1 mutants in the absence of FASN inhibition 
(Fig. 4 D, third bar) also showed a significant reduction in free 
palmitate levels. These levels were further reduced when Pink1 
mutants were treated with Cerulenin (Fig. 4 D, last bar).
The lower levels of free palmitate (and the trend toward 
lower free fatty acids) in Pink1 mutants may at least partially 
be explained by our observation that Pink1 mutant cells from 
mice and patients harbor lower FASN protein levels, as revealed 
by Western blotting (Fig. 4, E–H). It is well known that Pink1 
mutant cells harbor increased reactive oxygen species (ROS; He 
et al., 2008; Esposito et al., 2013). We therefore tested whether 
lower cellular FASN levels can be caused by increased ROS, 
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Figure 1. Identification of dFasn2 as a dominant suppressor of pink1B9. (A) Ranking of suppression levels of a phenotypic screen performed with 10 
suppressors of pink1B9, prioritizing rescue of ATP levels, then mitochondrial morphological defects, then flying ability. Green denotes significant rescue, 
whereas red denotes mutant phenotype (arbitrary scale). (B–F) Suppression of pink1B9 mutant phenotypes by dFasn2/+ (pink bars) compared with pink1RV 
controls heterozygous for dFasn2 (black bars) using different dFasn2 alleles for flight (n = 50 flies; B), ATP levels (n = 10 assays; C), mitochondrial mor-
phology in muscles of third instar larvae (n = 20 muscle sections; D and E), and electron micrographs of adult thorax muscle mitochondria (n = 5 flies; F). 
Arrowheads in E denote mitochondrial aggregation (blebs). (B–D) Student’s t test: *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data represent percentages 
(B) or means (C and D) ± SEM. (E and F) Bars: (E) 5 µm; (F) 0.5 µm. 
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and we treated MEF cells with H2O2. This manipulation indeed 
resulted in lower FASN protein levels (Fig.  4, I and J), indi-
cating that increased ROS correlate with lower FASN protein 
levels (and thus with lower levels of free palmitate). Although 
Pink1 mutants already show lower FASN levels and lower free 
palmitate levels than controls, this reduction is clearly insuffi-
cient to rescue the Pink1-associated defects. Yet, as we show 
here, further lowering FASN (either genetically or pharmaco-
logically, resulting in both cases in lower free palmitate) does 
yield rescue of the phenotypes.
Inhibition of FASN increases CL levels in 
PINK1 mutants
Palmitate is involved in several downstream pathways, but this 
lipid also connects to mitochondrial function. Increasing the 
palmitate levels was shown to inhibit the production of CL, a 
lipid that is exclusive to the inner mitochondrial membrane and 
to the membranes of bacteria (Ostrander et al., 2001; Buratta et 
al., 2008). Unsaturated phosphatidyl glycerol (PG; not saturated 
PG) is a good substrate for CL synthase (CLS; Hoch, 1992; 
Rytömaa and Kinnunen, 1994; Bobyleva et al., 1997), and high 
Figure 2. Pharmacological inhibition of FASN rescues PINK1-deficient flight defects and ATP levels. (A) Simplified schematic representation of the en-
zymatic reaction catalyzed by FASN requiring one Acetyl-CoA and seven Malonyl-CoAs to produce one palmitate in a seven-step enzymatic process. 
Compounds Cerulenin, Irgasan, and Orlistat block FASN at the second, sixth, and seventh steps, respectively. (B–G) Suppression of pink1B9 phenotypes by 
supplementing the fly medium with Cerulenin (green bars; B and C), Irgasan (blue bars; D and E), or Orlistat (pink bars; F and G) compared with control 
fly medium (black bars) for flying ability (n = 50 flies; B, D, and F) and ATP levels (n = 10 assays; 100 µM for Cerulenin, 3 µM for Irgasan, and 100 µM 
for Orlistat; C, E, and G). 1-d-old flies were selected and placed on the medium for 3 d before measuring ATP levels on 4-d-old flies. Student’s t test: 
*, P < 0.05. Data represent percentages (B, D, and F) or means (C, E, G, and H) ± SEM.
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Figure 3. The effect of FASN inhibition is evolutionarily conserved. (A–C) Images (A) and quantification (B) of mitochondrial morphology (n = 20 muscle 
sections) in muscles of third instar larvae and electron micrographs of adult thorax muscle mitochondria (C; n = 5 flies) after Cerulenin incubation. Arrow-
heads in A denote mitochondrial aggregation (blebs). Boxes in C denote magnified areas. Bars: (A) 5 µm; (C) 0.5 µm. (D–F) ATP levels of Pink1−/− MEFs 
(n = 5 assays; D), patient fibroblasts (n = 5 assays of two independent control or patient lines; E), and dopaminergic neurons derived from iPSCs from 
patients (n = 3 assays of two independent control or patient lines; F) incubated with 10 µM Cerulenin (green bars) or with control medium (black bars). 
Student’s t test: *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data represent percentages (D–F) or means (B) ± SEM.
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levels of palmitate shift the balance toward more saturated PG 
(Fig. 5 A; Ostrander et al., 2001). We used shotgun lipidom-
ics and assessed PG levels in mitochondrial fractions of MEFs. 
Saturated PG levels were extremely low in controls and were 
below the detection limit in Pink1 mutant samples. Assessing 
unsaturated PG levels, we found that inhibition of FASN re-
sulted in a significant increase in most unsaturated PG species 
(Fig. 5 B). When inhibiting FASN, other lipid species were also 
expected to be affected. As indicated in Fig. S3, the differences 
we measured in isolated mitochondria from control cells with 
and without Cerulenin were not significantly different. None-
theless, the lower palmitate levels and increased unsaturated PG 
that we detected upon inhibition of FASN are very robust and 
consistent with our model.
Pink1 mutants are known to harbor increased mitochon-
drial ROS (He et al., 2008; Esposito et al., 2013), and high ROS 
levels are known to result in decreased levels of CL (Ruggiero 
et al., 1992; Ellis et al., 2005). In line with this, CL levels in 
mitochondrial fractions of Pink1−/− MEFs were significantly 
decreased compared with control MEFs (Fig. 5, C and D). Next, 
we tested the effect of inhibiting FASN using Cerulenin that 
causes increased levels of unsaturated PG (see previous para-
graph). We found that in Pink1−/− MEFs, the levels of all CL 
species measured were almost completely restored to control 
levels (Fig. 5, C and D). Hence, loss of FASN function results 
in more mitochondrial CL in Pink1−/− mutant MEFs.
Loss of FASN increases complex I function
PINK1−/− mutants show lower enzymatic activity of com-
plex I (Gautier et al., 2008; Morais et al., 2009). We there-
fore wondered whether the rescue by inhibiting FASN acts 
through bypassing this complex I defect. We detected that 
partial inhibition of FASN using genetic or pharmacologi-
cal tools restored the defective complex I enzymatic ac-
tivity in PINK1 mutant flies and in MEFs back to control 
levels (Fig.  6, A–C). The inefficient electron transport be-
tween complex I and ubiquinone in PINK1 mutants was 
previously shown to be the result of an inability to main-
tain phosphorylation of Serine 250 in the complex I subunit 
NdufA10 (Morais et al., 2014). Indeed, mitochondria from 
engineered mammalian cells expressing only phosphoryla-
tion-deficient NdufA10S250A transfer electrons less efficiently 
Figure 4. Loss of FASN decreases palmitate levels in Pink1 deficiency. (A and B) Free fatty acid levels are reduced in pink1B9 mutant flies and are further 
reduced by heterozygosity of dFasn2 in pink1B9 mutant flies (pink; A) or by Cerulenin (green) in pink1B9 mutants (B) compared with pink1RV control flies 
(black; n = 5 assays). (C and D) Free fatty acid levels (C) and palmitate levels (D) in Pink1−/− MEFs incubated with Cerulenin (green) are reduced compared 
with those not incubated with Cerulenin (black) and to Pink1+/+ control MEFs. n = 5 assays. (E–J) Quantification (E, G, and I) and images (F, H, and J) of 
protein levels of FASN normalized to actin in Pink1−/− MEFs (E and F), patient-derived fibroblasts (G and H), and H2O2-treated wild-type MEFs (I and J). 
n = 3 assays. Bonferri’s analysis of variance (A–D) and Student’s t test (E, G, and I): *, P < 0.05; **, P < 0.01; ns, not significant. Data represent percent-
ages (A–D) or normalized means (E, G, and I) ± SEM.
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from complex I to ubiquinone, similar to Pink1 mutant mi-
tochondria (Fig. 6 D). Interestingly, we found that pharma-
cological inhibition of FASN resulted in a restoration of this 
activity (Fig.  6  D), indicating that the inhibition of FASN 
bypasses this ETC defect.
CL increases complex I function
Our data are consistent with a model wherein Pink1 mutant mi-
tochondrial dysfunction is rescued because the loss of FASN re-
sults in increased mitochondrial CL. We challenged this model 
by taking three independent approaches. In our first approach, 
Figure 6. Loss of FASN improves complex I activity upon Pink1 deficiency. (A and B) Complex I activity normalized to citrate synthase (CS) in pink1B9 
mutant flies that were rescued by heterozygous dFasn21 in pink1B9 mutant flies (pink; A) or by inhibition of FASN by Cerulenin (green; B) in pink1B9 mutant 
flies compared with pink1RV control flies (black). n = 8 assays. (C) Complex I activity normalized to citrate synthase in Pink1−/− MEFs incubated with Ceru-
lenin (green) compared with those not incubated with Cerulenin (KD; black) and to Pink1+/+ control MEFs. n = 5 assays. (D) Complex I activity normalized 
to citrate synthase in cells where NdufA10 was knocked down (Morais et al., 2014) and where wild-type NdufA10 (WT) or phosphorylation-deficient 
NdufA10 (S250A) are reexpressed and then incubated with Cerulenin (green) or control medium (black). n = 4 assays. Student’s t test: *, P < 0.05; 
ns, not significant. Data represent percentages ± SEM.
Figure 5. Loss of Pink1 results in decreased 
CL levels. (A) Palmitate produced by FASN 
promotes the formation of saturated PG that 
is a weak substrate for CLS, thus resulting 
in lower CL levels. Lower levels of palmitate 
upon inhibition of FASN shift the balance to in-
creased levels of unsaturated PG, which serve 
as a strong substrate for CLS, thus producing 
more CL. (B–D) Shotgun lipid analysis of mito-
chondria isolated from Pink1−/− and Pink1+/+ 
MEFs (n = 2 independent experiments) that 
were incubated with Cerulenin (green bars) 
compared with those incubated with control 
medium (black bars) for PG separated by 
side chain unsaturation levels (B), CL alone 
(C), and CL separated by side chain unsatu-
ration level (D). Student’s t test: *, P < 0.05. 
Data represent means ± SEM.
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we fed flies an unrelated lipid, stearic acid, that was previously 
shown to rescue the climbing defect and lower ATP levels seen 
in Pink1-deficient flies (Senyilmaz et al., 2015). Unlike Cerule-
nin, stearic acid did not increase the activity of mitochondrial 
complex I in Pink1 mutants (Fig. S4). These data indicate the 
specificity of our approach and suggest that stearic acid rescues 
aspects of the Pink1 phenotype by acting through a different 
pathway than complex I (e.g., mitochondrial fission; Vilain et 
al., 2012; Senyilmaz et al., 2015).
In our second approach, we isolated mitochondria from 
Pink1 mutant flies or Pink1−/− MEFs and incubated them with 
different amounts of various lipids, including PG, phosphatidyl 
ethanolamine (PE), phosphatidyl choline (PC), and CL, while 
sonicating, thus allowing the lipid to incorporate (Fig. 7, A–D). 
Only CL, and not PG, PE, or PC, showed a strong rescue of the 
electron transfer activity defects in complex I of Pink1 mutants 
(Fig. 7, A–D). This effect was absent in control samples that 
underwent the same treatment and was also seen when using 
mitochondrial fractions from Pink1−/− MEFs (Fig. 7 E). Hence, 
directly supplementing Pink1 mutant mitochondria with CL can 
bypass the complex I defect.
In a final approach, we scrutinized our model using ge-
netics. CL is produced in mitochondria by CLS (Nowicki et al., 
2005; Acehan et al., 2011), and we observed that partial loss of 
CLS (CLSe01021/+) in fruit flies resulted in lower complex I ac-
tivity compared with the complex I activity measured in control 
flies (Fig. 7 F). This defect in complex I activity in CLS/+ ani-
mals was not rescued by the inhibition of FASN with Cerulenin 
(Fig. 7 F, first green bar). In addition, the rescue of complex I 
defects in Pink1 mutants by Cerulenin is lost in Pink1 mutants 
that are also mutants for CLS (Fig. 7 F, right green bar). These 
data further support the model wherein the rescue of complex 
I defects in Pink1 mutants by the inhibition of FASN follows 
a CL-dependent pathway.
CL stabilizes cristae and ETC supercomplexes (Pfeiffer et 
al., 2003; Friedman et al., 2015), but a role for this lipid in the 
direct regulation of electron transport between complex I and 
ubiquinone in animal mitochondria has not been assessed. As 
noted in the Loss of FASN increases complex I function sec-
tion, electron transfer in Pink1 mutant mitochondria is caused 
by defective NDU FA10 phosphorylation (Morais et al., 2014). 
We therefore tested the ability of CL to bypass the electron 
transfer defect in NdufA10S205A phosphorylation-deficient cells. 
We incubated mitochondria from such cells with CL and found 
that this manipulation efficiently rescued the complex I defects 
(Fig.  7  G). Hence, CL facilitates electron transport between 
complex I and ubiquinone, and increasing CL levels are suffi-
cient to bypass the defects in Pink1 and NdufA10S205A mutants.
Discussion
In this study, we present a previously uncharacterized function for 
the mitochondrial inner membrane lipid CL, and we show that in-
creased CL rescues Pink1-induced mitochondrial dysfunction. CL 
has been coupled to the maintenance of mitochondrial cristae struc-
ture, and it is key to maintaining ETC supercomplexes (Pfeiffer et 
al., 2003). We now expand on this and provide evidence that CL 
also couples electron transfer between complex I and ubiquinone 
to increase the efficiency of the ETC. Pink1 mutants and many spo-
radic PD patients suffer from such complex I defects. We find that 
CLS mutants show decreased electron transfer from complex I to 
ubiquinone; conversely, increasing CL levels by partial inhibition 
of FASN using genetics or pharmacology significantly rescues the 
mitochondrial defects in Pink1 mutant cells (in both mice and pa-
tients) as well as in the degenerative phenotypes and flight defects 
in adult fruit flies. Loss of FASN also affects the levels of other 
lipids in isolated mitochondria. However, we did not observe an 
improvement in complex I activity after the incubation of isolated 
mitochondria with these lipids, suggesting that these changes in 
lipid level likely are not significantly contributing to the PINK1 
mutant phenotypes, as we report in this study.
Thus, our work also indicates specificity to CL, as the bio-
chemical defect at complex I in Pink1 mutants is not affected by 
other lipids, including PG, PE, PC, and stearic acid.
Our data are consistent with a significant contribution of 
ETC defects to Pink1 pathology, but they also confirm that Pink1 
acts in multiple parallel pathways. Stearic acid was recently shown 
to rescue Pink1-associated defects in fruit flies by activating path-
ways that induce mitochondrial fission (Senyilmaz et al., 2015). 
We and others previously showed that mitochondrial fission acts in 
parallel to a role of Pink1 in regulating complex I activity because 
increasing mitochondrial fission in Pink1 mutants does not rescue 
their complex I defect (Vilain et al., 2012; Pogson et al., 2014). 
Similar to these findings, stearic acid treatment does not rescue the 
complex I defect of Pink1 mutants. These observations are in con-
trast to those of increasing CL levels: CL does rescue the complex I 
dysfunction, but our EM study shows that mitochondria still appear 
somewhat enlarged, as was also seen previously when expressing a 
phosphomimetic NDU FA10S250D in Pink1 mutant animals (Morais 
et al., 2014). Although targeting either pathway significantly im-
proves mitochondrial dysfunction such that the mutant flies can fly 
again, a strategy that targets both simultaneously may yield even 
stronger effects (Vilain et al., 2012).
Neurodegeneration and aging have been linked to changes 
in lipid composition. The lower CL levels may be the conse-
quence of mitochondrial stress, including increased ROS that 
accumulate because of inefficient electron transport in complex 
I (He et al., 2008; Esposito et al., 2013). Although it is rec-
ognized that upon mitochondrial stress, CL is relocated to the 
outer mitochondrial membrane (Garcia Fernandez et al., 2002) 
to serve as a recognition signal for the degradation of mitochon-
dria (Chu et al., 2013), the mitochondrial mass in Pink1 mutant 
flies or cells is not particularly lower compared with wild-type 
controls (Rakovic et al., 2013). Rather, the defective mitochon-
dria in Pink1 mutants that are not degraded can be rescued by 
increasing CL levels, and this manipulation appears sufficient 
and specific to restore a dense cristae structure and to bypass the 
complex I dysfunction in Pink1 mutants. Other phospholipids 
were not able to rescue the complex I defects like CL could, 
suggesting that these phospholipids do not significantly contrib-
ute to the rescue of complex I dysfunction in PINK1 deficiency.
The loss of Pink1 also correlates with lower palmitate lev-
els. The production of palmitate by FASN requires a considerable 
amount of energy (Wakil et al., 1983), a feat particularly relevant 
in the context of Pink1 mutants that harbor lower cellular ATP 
levels (Clark et al., 2006; Park et al., 2006). Pink1-defective cells 
may thus access other sources in an attempt to maintain free 
fatty acid levels. The lower FASN levels we observed in Pink1 
mutants and in H2O2-treated cells may be a protective mecha-
nism under such conditions of low cellular energy, but further 
work is needed here. The palmitate mass that we measured in 
Pink1 mutant samples may thus not be a simple reflection of 
direct cellular palmitate synthesis by FASN but a combination of 
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different contributing factors, such as lower uptake, less synthe-
sis, and more consumption. These findings support the idea that 
inhibiting FASN in Pink1 mutants not only restricts palmitate 
production, thus allowing more CL synthesis, but that this ma-
neuver may, to some extent, also help to conserve cellular energy.
Thus, we propose that the lower FASN levels or activity 
may help to conserve energy and, more significantly, result in 
increased levels of CL to facilitate electron transfer between 
complex I and ubiquinone. FASN is a major target in oncology 
and metabolic disease, and phase I trials to inhibit the enzyme 
are ongoing. However, unlike the need to strongly inhibit the 
enzyme in oncology applications, our genetic work predicts 
that in PD, partial inhibition is sufficient, thereby reducing 
the risk of side effects.
Figure 7. CL couples electron transport between complex I and ubiquinone. (A–D) Complex I activity normalized to citrate synthase (CS) in isolated mi-
tochondria from pink1 mutant flies and control flies after 60 min of sonication and incubation with different concentrations of CL (A), PG (B), PC (C), and 
PE (D). The phospholipids added include the fatty acyl chains that were observed in the lipidomics analysis for those specific lipids. (E) Complex I activity 
normalized to citrate synthase from isolated mitochondria from Pink1−/− and control Pink1+/+ MEFs with 500 pM CL compared with control medium for 
60 min. (F) Complex I activity normalized to citrate synthase of loss of CLS in control and Pink1-deficient flies. n = 5 assays. (G) Complex I activity nor-
malized to citrate synthase after incubation and sonication of mitochondria isolated from cells where NdufA10 was knocked down and where wild-type 
NdufA10 (WT) or phosphorylation-deficient NdufA10 (S250A) were reexpressed. n = 4 assays. Student’s t test: *, P < 0.05; ns, not significant. Data 
represent percentages ± SEM.
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Materials and methods
Fly genetics
w pink1B9 (FBgn0029891) and park1 (FBgn0041100) mutant and w 
pink1RV and parkRV control flies were provided by J. Park and J. Chung 
(Korea Advanced Institute of Science and Technology, Daejeon, South 
Korea; Cha et al., 2005; Park et al., 2006), parkΔ21 mutants were pro-
vided by G. Mardon (Baylor College of Medicine, Houston, TX; Pesah 
et al., 2004), and UAS-Fasn2 was provided by J. Montagne (Univer-
sité Paris-Sud, Orsay, France; Garrido et al., 2015). Deficiencies and 
P-element mutants were from the Bloomington Drosophila Stock Cen-
ter (Bier et al., 1989; Ashburner et al., 1990; Spradling et al., 1999; 
Mason et al., 2004; Parks et al., 2004; Ryder et al., 2007). dFasn21 
is y w eyFLP.GMR::LacZ; dFasn1 P[y+] P[FRT40A neo+] and con-
trol is y w eyFLP GMR::LacZ; P[y+] P[FRT40A neo+] (Verstreken et 
al., 2005). k05816 (FBgn0042627) is y1 w67c23; P{lacW}FASN2k05816/
CyO and EP695 is w1118; P{EP}FASN2EP695/CyO. The 10 ethyl meth-
anesulfonate screen mutants are y w eyFLP GMR::LacZ; P[y+] 
P[FRT40A neo+] *mutant (Verstreken et al., 2005). CLS flies are w1118; 
PBac{RB}CLSe01021/TM6B, Tb1.
Cells
Pink1−/− MEFs were previously described (Morais et al., 2009). In 
brief, heterozygous Pink1 knockout mice (Pink1+/−) were interbred to 
generate mutant mice and wild-type littermate controls. At embryonic 
day 13, embryos were dissected into cell culture dishes containing 
DMEM supplied with 50% FCS and 1% penicillin/streptomycin. Cul-
tures were expanded and serum concentration was constantly decreased 
to 10% FCS after they reached consistent growth. Afterward, the cul-
tures were immortalized by transfection with SV40 large T antigen.
The NdufA10 HeLa cells were described and characterized 
previously (Morais et al., 2014). In brief, the HeLa NdufA10 down- 
regulated cell line was generated using shRNA against human NdufA10 
(targeted sequence, 5′-CAG AAG AAA GGA GAT CCA CAT GAA ATG 
AA-3′) according to the supplier’s protocol (OriGene) and were se-
lected based on their acquired puromycin resistance.
We have studied fibroblast cultures from two PINK1 mutation 
carriers harboring homozygous p.Q456X and p.V170G mutations (fe-
male, mean age 80 ± 0.7 yr; mean age at onset: 46 ± 21 yr). In addition, 
two cultures from healthy control individuals were included (female, 
mean age 51 ± 4.9 yr) that are family members from the patient carry-
ing the p.Q456X mutation (Grünewald et al., 2009).
The iPSC lines were differentiated into dopaminergic neurons as 
described previously (Kriks et al., 2011; Munsie et al., 2015). In brief, 
iPSC colonies were dissociated into single cells using accutase (Thermo 
Fisher Scientific) and replated onto matrigel-coated dishes (BD). Once 
iPSCs reached a confluence of 100%, neural differentiation was initi-
ated by adding knockout serum replacement medium supplemented 
with the SMAD pathway inhibitors SB431542 (Tocris Bioscience) and 
LDN-193189 (Stemgent). During the first 20 d, several growth factors 
and small molecules were added to the cell culture medium at various 
time points as indicated in the previously published protocol (Kriks et al., 
2011) to pattern the neurons into the dopaminergic lineage (floor plate 
induction). On day 21 of the differentiation, cells were dissociated using 
accutase and plated at a high density (50-µl drop with 350,000 cells) 
onto the center of culture dishes, which had been previously coated with 
poly-d-lysine (Sigma-Aldrich) and laminin (Roche), in medium for ter-
minal differentiation (Kriks et al., 2011). Neurons were aged for ∼50 d.
Feeding experiments
1-d-old adult flies were placed on molasses medium supplemented 
with 100 µM Cerulenin (Enzo Life Sciences), 3 µM Irgasan (Sigma- 
Aldrich), or 100  µM Orlistat (Sigma-Aldrich), unless otherwise in-
dicated in Fig. 2 (B, D, and F; 2.5% final ethanol concentration), or 
flies were supplemented with 2.5% ethanol for control medium. The 
animals were kept on these media for 72  h and tested for flight or 
ATP levels. To determine mitochondrial morphology, embryos were 
placed in molasses medium supplemented with 100  µM Cerulenin 
(2.5% final ethanol concentration) or with 2.5% ethanol for control 
medium and grown to the third instar larval stage. These third instar 
larvae were dissected and used for experiments (see Determination of 
mitochondrial morphology).
To assess ATP levels in the cells, cells were treated with 10 µM 
Cerulenin for 24  h (0.1% ethanol) or with control medium supple-
mented with 0.1% ethanol. For Western blotting analysis, wild-type 
MEFs were treated with 100 µM H2O2 for 30 min.
Flight and survival
The flight assay was conducted on male flies using batches of five flies 
each. The flies were placed in an empty vial and gently tapped. The flies 
that were able to fly were given a score of 1, whereas those that did not 
fly were given a score of 0.
For survival, the latest survival stage of animals is indicated 
for animals that were reared on grape juice plates with yeast paste 
in uncrowded conditions.
ATP determination
ATP levels were determined as previously described (Park et al., 2006; 
Morais et al., 2014) using an ATP determination kit (Invitrogen) ac-
cording to the supplier’s protocol. Luminescence was measured on a 
luminometer (Bio-Rad Laboratories), and values were normalized to 
total protein content using the Bradford method.
Mitochondrial isolation and complex I activity measurements
Flies and cells were homogenized in 1-ml chilled mitochondrial isola-
tion medium (Abcam) and then spun twice at 1,000 g for 5 min. The 
supernatant was collected and spun at 13,000 g for 5 min followed by 
a washing step of the pellet containing the mitochondria with 1 ml of 
mitochondrial isolation medium and was resuspended in 50 µl isola-
tion medium. The samples were kept at 4°C during the entire process 
(Walker et al., 2006; Frezza et al., 2007). Mitochondrial isolates were 
sonicated (10 pulses at 20%) and used to measure complex I activity 
as previously described (Fischer et al., 1986; de Paepe et al., 2006). 
In brief, to measure NADH:O2 oxidoreductase activity, mitochondrial 
isolates were buffered in medium containing phosphate buffer (0.1 M, 
pH 7.4), BSA (10 mg/ml), NADH (1 mM), and KCN (30 mM). Decy-
lubiquinone, a ubiquinone analogue, was added to accept the electrons 
from complex I and to activate the reaction. The activity of NADH 
oxidation was spectrophotometrically followed at 340 nm at 37°C and 
was corrected for rotenone-insensitive NADH oxidation. Values were 
normalized to citrate synthase activity.
For phospholipid incubation, isolated mitochondria underwent 
freeze-thaw steps and sonication and were then incubated for 60 min 
with various concentrations of the different lipids at 37°C before com-
plex I activity measurements. The phospholipid analysis revealed that 
the monounsaturated fatty acyl chains are most abundant (except for 
CL). Therefore, the following phospholipids were used: CL (LM-
6003), PC (850457C), PG (840457C), and PE (850757C).
Western blotting
Cells were collected and diluted in Laemmli sample buffer and were 
boiled for 5 min. 15 µg of proteins were separated on precast 4–12% 
NuPage Bis-Tris gels (Invitrogen). Blots were probed with the following 
primary antibodies: 1:1,000 rabbit anti-FASN and 1:1,000 anti–β-actin 
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(Abcam). The membranes were developed with Western Lightning 
ECL (PerkinElmer) and imaged. Quantification was performed using 
the gel analyzer tool in ImageJ software (National Institutes of Health).
Determination of mitochondrial morphology
Larvae were dissected in HL-3 (Stewart et al., 1994) and larval fillets 
were fixed in 4% formaldehyde in PBS for 20 min and permeabilized 
with 0.4% Triton X-100. Primary antibody monoclonal mouse anti- 
ATP synthase B (1:200; Abcam) was used to visualize mitochondria. 
We used goat anti-mouse Alexa Fluor 555 (1:1,000) as a secondary 
antibody. Images were visualized with a confocal microscope (A1R) 
through a near-infrared Apo 60× 1.0 NA water dipping lens (Nikon) 
in room temperature. Images were acquired using the NIS-Elements 
Advanced Research software package (Nikon). Images were quantified 
using the analyzing particles plugin in ImageJ, with which rounded 
mitochondria were automatically detected and counted.
Electron microscopy
Electron microscopic analyses of thorax mitochondria were performed 
as previously described (Esposito et al., 2013). In brief, thoraxes of 
adult flies were fixed in paraformaldehyde/glutaraldehyde, postfixed 
in osmium tetroxide, dehydrated, and embedded in epon. 80-nm-thick 
sections were stained with uranylacetate end lead citrate, sections were 
imaged using a transmission electron microscope (TEM 1400; JEOL) 
at room temperature and a bottom-mounted camera (11 MP; Quemesa; 
Olympus), and iTEM 5.2 software (ResAlta Research Technologies) 
was used to acquire micrographs. Mitochondrial morphology was an-
alyzed using ImageJ and scored in a blinded fashion as normal mito-
chondria with organized cristae or as swollen mitochondria devoid of 
cristae from five flies. For each fly, five sections were analyzed.
Free fatty acid measurement
30 adult flies were homogenized in 5% isopropanol and 5% Triton 
X-100 and prepared according to the manufacturer’s protocol (Bio- 
Assay Systems). The amount of free fatty acids was analyzed by mea-
suring optic density at 570 nm on a Multilabel reader (Biotek). Values 
were normalized to protein content.
Free palmitate measurement
One million cells were plated in 6-well plates and incubated with Ceru-
lenin for 24 h before sample collection. Metabolites for the subsequent 
mass spectrometry analysis were prepared by quenching the cells in 
liquid nitrogen followed by a cold two-phase methanol/water/chloro-
form extraction (Christen et al., 2016). During the extraction, samples 
were constantly refrigerated in a dry ice/ice mixture. Each sample was 
scraped in 800 µl of a 3:5 water/methanol solution and collected in a 
1.5-ml tube. Norvaline (0.75 µg/sample) and glutarate (0.75 µg/sample) 
were added as internal standards for polar metabolites. Next, 500 µl 
chloroform was added to each sample. Heptadecanoate (5 µg/sample) 
was also added as an internal standard for fatty acids. Samples were 
vortexed for 10 min at 4°C, and phase separation was then achieved 
by centrifugation at 4°C at maximum speed for 10 min on a refriger-
ated bench-top centrifuge. The water/methanol phase containing polar 
metabolites, the chloroform phase containing fatty acids, and the inter-
phase containing proteins and DNA were separated and dried using a 
vacuum concentrator. Dried metabolite samples were stored at −80°C 
until further processing. Fatty acids were esterified with 2% sulfuric 
acid in methanol, shaken for 15 min at room temperature, and subse-
quently extracted by addition of 600 µl hexane and 100 µl of saturated 
NaCl per sample, followed by vortexing for 10 min and centrifuga-
tion at 4°C at maximum speed for 5 min on a refrigerated bench-top 
centrifuge. The hexane (upper) phase was transferred to new 1.5-ml 
tubes and dried using a vacuum concentrator. Samples were then re-
suspended in 25–100 µl hexane, vortexed for 10 min, and transferred 
to glass vials for gas chromatography–mass spectrometry analysis. The 
method was tested on free fatty acid and triglyceride standards and 
was verified to specifically esterify free fatty acids. Metabolite levels 
were measured with a gas chromatography system (7890A) combined 
with an inert mass spectrometry system (5975C; Agilent Technologies) 
as described previously (Lorendeau et al., 2016). Specifically, 1 µl of 
sample was injected into a DB35MS column (Agilent Technologies) 
in splitless mode using an inlet temperature of 270°C.  The carrier 
gas was helium with a flow rate of 1 ml/min. Upon injection, the gas 
chromatography oven was held at 80°C for 1 min and then ramped 
with 5°C/min to 300°C. The mass spectrometry system was operated 
under electron impact ionization at 70 eV, and a mass range of 100–650 
atomic mass units was scanned. The palmitate peak was identified 
based on a standard curve, and the area under the curve of the palmitate 
peak was integrated using a MatLab M file, published by Young et al. 
(2008), which applies consistent integration bounds and baseline cor-
rection to each ion. The total ion counts for palmitate of each sample 
was compared with a blank extraction without cells to correct for the 
eventual presence of noncellular tracers of palmitate. The data were 
normalized over total DNA content. For this purpose, total DNA was 
extracted from the interphase with the DNeasy Blood and Tissue kit 
(QIA GEN) and quantified with a spectrophotometer (Nanodrop 2000; 
Thermo Fisher Scientific).
Lipid extraction for mass spectrometry lipidomics
Mass spectrometry–based lipid analysis was performed at Lipotype 
GmbH as described previously (Sampaio et al., 2011). Lipids were 
extracted using a two-step chloroform/methanol procedure (Ejsing et 
al., 2009). Samples were spiked with internal lipid standard mixture 
containing CL 16:1/15:0/15:0/15:0, ceramide 18:1:2/17:0, diacylglyc-
erol 17:0/17:0, hexosyl ceramide 18:1:2/12:0, lysophosphatidate 17:0, 
lysophosphatidyl choline 12:0, lysophosphatidyl ethanolamine 17:1, 
lysophosphatidyl glycerol 17:1, lysophosphatidyl inositol 17:1, lyso-
phosphatidyl serine 17:1, phosphatidate 17:0/17:0, PC 17:0/17:0, PE 
17:0/17:0, PG 17:0/17:0, phosphatidyl inositol 16:0/16:0, phosphatidyl 
serine 17:0/17:0, cholesterol ester 20:0, sphingomyelin 18:1:2/12:0:0, 
triacylglycerol 17:0/17:0/17:0, and cholesterol D6. After extraction, 
the organic phase was transferred to an infusion plate and dried in a 
speed vacuum concentrator. First-step dry extract was resuspended in 
7.5 mM ammonium acetate in chloroform/methanol/propanol (1:2:4; 
V:V:V), and second-step dry extract was resuspended in 33% ethanol 
solution of methylamine in chloroform/methanol (0.003:5:1; V:V:V). 
All liquid handling steps were performed using the STARlet robotic 
platform with the Anti-Droplet Control feature for organic solvents pi-
petting (Hamilton Robotics).
Mass spectrometry data acquisition
Samples were analyzed by direct infusion on a mass spectrometer 
(QExactive; Thermo Fisher Scientific) equipped with an ion source 
(TriVersa NanoMate; Advion Biosciences). Samples were analyzed 
in both positive and negative ion modes with a resolution of mass/
charge ratio = 200 = 280,000 for mass spectrometry and Rm/z = 200 
= 17,500 for tandem mass spectrometry experiments in a single ac-
quisition. tandem mass spectrometry was triggered by an inclusion list 
encompassing corresponding mass spectrometry mass ranges scanned 
in 1-D increments (Surma et al., 2015). Both mass spectrometry and 
tandem mass spectrometry data were combined to monitor CE, diacyl-
glycerol, and triacylglycerol ions as ammonium adducts; PC and PC 
O− as acetate adducts; and CL, phosphatidate, PE, PE O−, PG, phos-
phatidyl inositol, and phosphatidyl serine as deprotonated anions. Mass 
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spectrometry only was used to monitor lysophosphatidate, lysophos-
phatidyl ethanolamine, lysophosphatidyl ethanolamine O−, lysophos-
phatidyl inositol, and lysophosphatidyl serine as deprotonated anions; 
ceramide, hexosyl ceramide, sphingomyelin, lysophosphatidyl choline, 
and lysophosphatidyl choline O− as acetate adduct; and cholesterol as 
an ammonium adduct of an acetylated derivative (Liebisch et al., 2006).
Data analysis and postprocessing
Data were analyzed with in-house developed lipid identification soft-
ware based on LipidXplorer (Herzog et al., 2011, 2012). Data post-
processing and normalization were performed using an in-house 
developed data management system. Only lipid identifications with a 
signal-to-noise ratio of >5 and a signal intensity fivefold higher than in 
corresponding blank samples were considered for further data analysis.
Statistics
Statistical analyses was performed using Prism software (GraphPad), 
and to assess whether the observed data points were significantly dif-
ferent, we used a two-tailed Student’s t test when comparing two con-
ditions or one-way analysis of variance with Bonferroni’s post-hoc test 
when comparing more than two conditions. P-values were considered 
significant when they were <0.05.
Online supplemental material
Fig. S1 shows the identification of the suppressive alleles in pink1B9 
mutant flies. Fig. S2 shows that inhibition of FASN results in the sup-
pression of pink1B9 mutant flies, but not in the suppression of Parkin 
mutant flies. Fig. S3 shows the levels of various phospholipids in 
Pink1−/− MEFs upon inhibition of FASN. Fig. S4 shows the complex 
I activity of pink1 mutant flies that were pretreated with stearic acid.
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